Key Highlights

  • Shares are trading 2.66% higher at $4.57 on Wednesday, October 28, 2026.
  • Short interest was 17,214,886 shares at the October 15 settlement, up 331,997 from the prior period.
  • Days to cover were 12.70, with the short count equal to about 30.1% of shares outstanding.
  • Zevaskyn net product revenue was $11.4 million in the second quarter, up 31% from $8.7 million.
  • Cash, equivalents and short-term investments were $146.8 million at June 30, 2026.

Abeona Edges Higher: What Is Behind the Move in a Crowded Short Trade?

Abeona Therapeutics (NASDAQ:ABEO) shares are trading 2.66% higher at $4.57 on Wednesday, October 28, 2026, an implied prior close of about $4.45 (calculated). At that price the market capitalization is roughly $261 million (calculated from 57.18 million shares).

No dated company release accompanied the move. The latest milestones are operational: the Medicare technology add-on payment for Zevaskyn took effect on October 1, 2026, and Cincinnati Children's was activated as a treatment center in the third quarter.

Abeona is a commercial-stage cell and gene therapy company. Its product Zevaskyn treats recessive dystrophic epidermolysis bullosa, a severe inherited skin disease, and its pipeline includes ABO-503 for X-linked retinoschisis, an inherited eye disease.

Short Interest at 17.2 Million Shares: What Could 12.7 Days to Cover Imply?

Short-interest data for the settlement date of October 15, 2026 show 17,214,886 shares sold short, up 331,997 from 16,882,889 at the prior settlement. That is about 30.1% of the 57.18 million shares outstanding (calculated), and days to cover were 12.70.

With that many days of average volume needed to close the position, buying pressure could be amplified if shorts cover, while the same crowding leaves the shares exposed to selling if sentiment weakens. The figure describes positioning and does not predict direction.

Zevaskyn Launch Metrics: How Fast Is Revenue Building?

Second-quarter net product revenue from Zevaskyn was $11.4 million, up 31% from $8.7 million in the first quarter, bringing six-month product revenue to $20.1 million. Five patients were treated in the quarter, but revenue was recognized for four because one batch had a cell yield below the required threshold.

Three more treatments were completed in the third quarter through the August 13 report, for 12 patients since launch. The treatment network stood at seven qualified centers, and Cincinnati Children's was added afterward.

Reports on the launch noted that the Medicare add-on payment, effective for federal fiscal 2027, was one of only three approvals among 15 applications in the cycle. The payment is intended to ease hospital reimbursement for the therapy.

Cash Burn and Net Loss: Is the Balance Sheet Keeping Pace With Spending?

The second-quarter net loss was $20.2 million, or $0.35 per share, compared with $17.1 million, or $0.30, in the first quarter. Research and development expense was $5.0 million and selling, general and administrative expense was $15.8 million, which reflects the commercial build-out. The six-month net loss was $37.3 million.

Cash, equivalents and short-term investments were $146.8 million at June 30, down from $191.4 million at December 31, 2025, a fall of about $44.6 million in six months (calculated). The release gave no guidance and did not state a cash runway.

What to Watch Next: Third-Quarter Results and the October 30 Short-Interest Settlement

The next short-interest settlement is October 30, 2026, with publication expected around November 10. Abeona reported third-quarter results on November 12 last year, so the next update on patient treatments, recognized revenue and cash is expected in mid-November, with ABO-503 IND-enabling studies guided for the second half of 2026.